Evidence map›Paper›PMID 28483810›Full record

ArticleJournal of health politics, policy and law2017

Evidentiary Support in Public Comments to the FDA's Center for Tobacco Products.

Natalie Hemmerich, Elizabeth G Klein, Micah Berman

Abstract read
In one paragraph

Article in Journal of health politics, policy and law, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Natalie HemmerichOhio State University.
Elizabeth G KleinOhio State University.
Micah BermanOhio State University.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Project 4: Comprehension of Health Risks in More and Less Arousing Affe p240-275P50CA180908 · NCI · OHIO STATE UNIVERSITY · PI SHIELDS, PETER G., WEWERS, MARY ELLEN · 2013 to 2017
$18.9M
NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA180908
6 · The paper itself

Abstract

Electronic Nicotine Delivery Systems (ENDS) were introduced into the US market in 2007, and until recently these devices were unregulated at the federal level. In 2014, the US Food and Drug Administration (FDA) published a Notice of Proposed Rulemaking asserting its intention to regulate ENDS and requesting public comments on numerous related issues, including potential limits on the sale of flavored ENDS. This article analyzes key comments submitted to the FDA on the issue of flavor regulation in ENDS and examines the weight and credibility of the evidence presented by both supporters and opponents of regulation. It also describes the final deeming rule, published in May 2016, and the FDA's response to the evidence submitted. This is the first study to examine public comments submitted to the FDA's Center for Tobacco Products, and it concludes that opponents of regulation were more likely to rely on sources that were not peer reviewed and that were affected by conflicts of interest. In light of these findings, the FDA and the research community should develop processes to carefully and critically analyze public comments submitted to the FDA on issues of tobacco regulation.

Indexed as

Community ParticipationElectronic Nicotine Delivery SystemsPublic OpinionUnited States Food and Drug AdministrationCommerceFlavoring AgentsHumansUnited StatesFlavoring Agentsdeemingelectronic nicotine delivery systemsflavorsFood and Drug Administrationtobacco regulatory science

Identifiers

PMID28483810
PMCPMC5522345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.